Financial News · Live Terminal

Page 149 of 324

Research Alert: CFRA Maintains Buy Rating On Shares Of Hubspot, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $221, from $310, on an EV/S multiple of 2.3x our 2027 sales projection of $4.289B, below its three-year average. We increase our 2026 EPS estimate to $13.11 from $12.47 and raise our 2027 EPS view to $15.58 from $15.07. HUBS reported solid Q1 results with subscription revenue growing 23% Y/Y, driven by strong upmarket momentum as deals over $60K ARR grew 37% and deals over $120K ARR surged 64%. Multi-hub adoption continued, while AI monetization was encouraging as active core seat users grew 90% Y/Y with over 25% of Pro+ customers purchasing additional core seats (up 12+ points). Non-GAAP operating margin expanded significantly to 17.8%, up 4 points Y/Y, and HUBS raised its full-year 2026 operating margin guidance to 21% (+100 bps). While pricing/GTM changes creates uncertainty and led to lighter guidance, we expect headwinds to be transitory as demand for its core platform and AI tools showed strength.

$HUBS

Research51d ago

Cineplex Target Eased To C$13.50 From $14, Keeps Outperform at National Bk Which Notes Q1 Revs & Adj. EBITDAaL Below Elevated Street, Media & LBE Light, But Box Office Delivering

$CGX.TO

Research51d ago

Barrick Mining Target Raised To C$75 From $72.50, Keeps Outperform at National Bank On "Incorporating a Strong Start to the Year"

$ABX.TO

Research51d ago

Research Alert: CFRA Raises Rating On Shares Of West Pharmaceutical Services To Strong Buy From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price is $390, raised from $350. This is 45.2x our 2026 EPS estimate (up $0.09 to $8.62; 2027 estimate up $0.13 to $9.55), above WST's five- and 10-year forward averages of 41.9x and 42.2x, respectively. Our valuation reflects the strength of the HVP business, with capital expansion plans for additional HVP capacity, as well as a growing market for GLP-1 elastomer sales and significant balance sheet health (negative net debt). WST leads all S&P Composite 1500 Life Sciences Tools and Sevices firms in YTD performance (+18% through May 8) despite significant pressure on the sub-industry (-17%). We think WST remains well positioned to benefit from GLP-1 demand as well as non-GLP-1 biologics growth, offering less exposure to cyclicality in academia/government R&D budgets and adverse China policies that we think are pressuring peers. We see near-term sales, margin, and earnings growth supporting WST's valuation, with negative net debt supporting financial flexibility and lowering downside risk.

$WST

Research51d ago

Extendicare Target Raised To C$34 From $32, Keeps Outperform at National Bank As "Strong Fundamentals Support Valuation"

$EXE.TO

Research51d ago

Fiera Capital Target Eased To C$6 From C$7, Keeps Sector Perform at National Bank On EBITDA Miss and Ongoing Net Outflows In Q1 2026

$FSZ.TO

Research51d ago

Research Alert: CFRA Keeps Hold View On Shares Of Moderna; Shares +16% Amid Andes Outbreak

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MRNA shares rose over 16% in five days following an Andes virus (rare hantavirus strain) outbreak on cruise ship MV Hondius. The vessel, carrying ~150 passengers from 23 countries, departed Argentina on April 1 and docked in the Canary Islands on May 10 with six confirmed cases, two probable cases, and three deaths. While no hantavirus vaccine currently exists, mRNA technology offers advantages including rapid development, strain adaptability, and stronger immune response versus traditional vaccines. Moderna is developing an mRNA hantavirus vaccine with Korea University, though the program remains in early preclinical stages (animal studies only), suggesting substantial time is needed despite current market enthusiasm. Health officials assess the pandemic risk as low given the virus requires close, prolonged contact for transmission. The Andes virus is the only known hantavirus strain to spread person-to-person. We raise our target to $58 from $48 based on NPV analysis, maintain our 2026 LPS at -$7.95, and keep 2027 LPS at -$4.82.

$MRNA

Research51d ago

Research Alert: CFRA Cuts Opinion On Shares Of Ingredion Incorporated To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our 12-month target to $119 from $137, ~11x our 2026 EPS of $10.83 (cut from $11.43; 2027 EPS cut to $11.84 from $12.37) vs. the 13x long-term mean. Our revised outlook reflects ongoing challenges at the Argo facility, one of the company's largest manufacturing sites. In April 2026, this facility experienced its third major disruption in 18 months. While management has characterized these as separate incidents, the pattern suggests underlying operational issues. This latest disruption and associated costs prompted the company to lower its full-year EPS guidance. Additional headwinds include Mexican peso strength (costs are peso-denominated), rising energy prices, packaging inflation, tariffs, and concerns about indirect impacts on consumer demand in 2H 2026. Given the prolonged margin recovery in the F&II-U.S./Canada segment, we believe it is prudent to move to a Hold rating.

$INGR

Research51d ago

Research Alert: CFRA Reiterates Buy Opinion On Shares Of News Corp

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $2 to $31, 26x our FY 27 (Jun.) EPS estimate (unchanged multiple). We raise our FY 26 EPS estimate to $1.03 from $0.99 and FY 27's to $1.19 from $1.13. Following FQ3 (Mar-Q) results, we are reiterating our Buy opinion. We are encouraged by results at Dow Jones, where revenue growth is accelerating in its Risk & Compliance (+19% Y/Y) and Energy (+12% Y/Y) products. The Dow Jones segment also saw Wall Street Journal subscriptions reach 4.7M (+8% Y/Y) despite higher subscription prices, demonstrating pricing power. The company's Digital Real Estate Services grew revenue (+8% Y/Y ex-FX) despite new and existing home sales remaining in a slump. Adjusted EBITDA margins have expanded for eight consecutive quarters post-Foxtel spin-off, fueling improved free cash flow and accelerated buybacks. At 26x our FY 27 estimate vs. a 29x five-year average, shares trade at a discount with potential for re-rating as operational momentum continues.

$NWSA

Research51d ago

Research Alert: CFRA Keeps Hold Rating On Shares Of Genpact Limited

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price by $9 to $36, 8.3x our 2027 EPS estimate vs. G's three-year historical forward P/E average of 12.1x and the peer average of 11.6x. We raise our 2026 EPS view to $4.04 from $3.99 and keep 2027's unchanged at $4.34. We think G faces operational risks, including execution hurdles in scaling its new AI-driven offerings against intense competition. However, these concerns are partly overshadowed by the exceptional momentum in its strategic pivot, highlighted by a 24% surge in ATS revenue. In a major proof point of this shift, the company secured nearly double the contract value for its new Agentic solutions in Q1 alone compared to all of 2025, demonstrating rapid market adoption. This successful transition towards higher-margin, IP-based recurring revenue is structurally improving profitability, evidenced by 12 consecutive quarters of gross margin expansion. Sustaining this high-stakes execution and improving cash conversion remain critical to fully de-risking the company's transformation.

Research51d ago

Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Epam Systems, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target from $231 to $184, 14x our 2026 EPS view, below EPAM's three-year average (19x) on AI competition risk. We raise our 2026 EPS view by $0.31 to $13.13 and 2027's by $0.23 to $14.53. Profitability continues to improve, supported by operational discipline and improved pricing in certain cases, which helps provide support to our view that EPAM is favorably positioned for more AI-focused projects. To this point, EPAM's AI revenues continue to grow solidly, up 19% Q/Q to $125M in Q1 for the fifth-straight double-digit sequential increase. Despite more bearish fears that the company's revenue deceleration (with its 2026 organic CC guide coming down to ~5.25% from ~6% prior), we see clear negative impacts from macro factors (i.e., the war in Iran) that should prove temporary, allowing for multiple expansion once these factors fade and AI deal momentum becomes more clear. Still, our lower target reflects heightened risks of perceived AI competition as impressive new AI models continue to roll out.

$EPAM

Research51d ago

Research Alert: CFRA Maintains Buy Opinion On Shares Of Grab Holdings Limited

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our USD4.50 target price for Grab, valuing the stock at 26.5x 2026 EV/EBITDA, above its peer average forward EV/EBITDA of 10.6x. We keep our 2026/2027 EPS estimates unchanged. Our Buy rating is supported by strong momentum continuing into Q1 2026. The strategic acquisition of foodpanda Taiwan marks Grab's first expansion outside Southeast Asia, adding a profitable USD1.8 billion GMV market expected to be accretive to 2026 revenue. This move positions Grab well toward its ambitious 2028 target of USD1.5 billion in Adjusted EBITDA. The USD400 million share buyback program further reinforces management's confidence in value creation. Despite near-term headwinds from elevated crude oil prices that may pressure driver margins and consumer demand, we believe Grab's diversification across delivery and financial services, combined with its market-leading position in the high-growth Southeast Asia region, provides meaningful resilience to sustain its long-term profitable growth trajectory.

$GRAB

Research51d ago

Research Alert: CFRA Reiterates Buy Opinion On Adss Of Embraer S.a.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our unchanged 12-month target price of USD79 values EMBJ at 22.1x our 2027 EPS estimate, a premium relative to EMBJ's two-year average forward P/E of 18.4x but a discount to peers' average forward P/E of 25.9x. We lower our 2026 earnings per ADS estimate by BRL1.02 to BRL12.97 and 2027 by BRL1.39 to BRL17.50, mostly due to the exchange rate. Management reiterated full-year 2026 guidance of 80-85 commercial aircraft deliveries, 160-170 executive jet deliveries, revenue of USD8.2B-USD8.5B, and adjusted EBIT margin of 8.7%-9.3%. The firm order backlog reached an all-time high of USD32.1B (+22% Y/Y), with Commercial Aviation backlog up 50% Y/Y driven by a 3.0x book-to-bill ratio. A major milestone came with the UAE's order for 10 C-390 aircraft plus 10 options, opening Middle East opportunities. By decade-end, EMBJ targets production of 120 commercial jets, 200 executive jets, and 10 KC-390s annually, supporting management's ambition for double-digit revenue growth and double-digit EBIT margins in the medium term.

$EMBJ

Research51d ago

Northview Residential REIT Target Raised To C$19 From $18, Keeps Sector Perform at National Bk As Q1 FFO "In Line Despite Seasonal op-cost drag

$NRR-UN.TO

Research51d ago

Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Coinbase Global, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target at $235 on EV/sales of 7.1x our 2027 sales estimate and 17.8x 2027 EBITDA. We decrease our 2026 EPS estimate by $1.93 to $1.41 and lower 2027's by $2.04 to $5.75. Despite a volatile Q1 for the broader crypto market, COIN was able to deliver retail derivatives ($200M run-rate) and newly launched prediction market ($100M run-rate) revenue growth above our estimates. Management believes the CLARITY Act is likely to pass this summer and we see this creating tailwinds for further stablecoin growth, but note COIN may face fee compression as new entrants begin entering the stablecoin market. COIN is proactively reducing both headcount and expenses in 2H 2026 during what we have anticipated will be a weak year for BTC and ETH after selling off in Q4 2025. Our 2027 outlook continues to see EBITDA margin expansion with subscription and services revenue growing faster than transaction-based revenue streams, creating a stronger/less volatile revenue mix in the long term.

$COIN

Research51d ago

Dream Office REIT Target Edged Up To C$19.50 from $19, Keeps Sector Perform at National Bank On Meaningful in-place occupancy build expected in the Toronto portfolio in 2026

$D-UN.TO

Research51d ago

Research Alert: CFRA Maintains Buy Rating On Emera On Strong Adjusted Eps, Florida Strength

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our Buy rating on EMA and maintain our target price of CAD83. The target price continues to be derived from our earnings multiple of 21.0x, applied to our 2027 adjusted EPS. We increase our 2026 EPS view by CAD0.23 to CAD3.67 and 2027's by CAD0.05 to CAD3.98. The Utilities space remains attractive as a defensively positioned sector amid inflationary macroeconomic conditions. Q1 2026 adjusted EPS of CAD1.37 exceeded expectations, and management believes 2026 adjusted EPS can exceed the 5%-7% growth guidance. All major projects are progressing as planned, and CAD870M of capital was deployed in Q1.

$EMA

Research51d ago

South Bow Target Edged Up To US$31 From $30, Keeps Sector Perform at National Bank On Q1

$SOBO.TO

Research52d ago

Research Alert: Fox Corporation Reports Earnings And Revenue Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:FOXA delivered solid Q3 FY 26 (Jun.) results with adjusted EPS of $1.32 vs. $1.10 prior year, beating consensus by $0.35. Revenue of $3.99B beat the $3.81B consensus estimate. Adjusted EBITDA rose to $954M from $856M, led by operational discipline and cost management across segments. We continue to see strong sports and news franchises providing pricing power and audience engagement, with NFL content delivering higher ratings and advertising demand, indicating margin expansion potential. FOXA will deliver the FIFA World Cup in the U.S. with an expanded 104-match schedule over five weeks, providing significant exposure opportunity. Tubi revenue grew a healthy 23% in Q3, building on nearly 100M monthly active users who will engage with World Cup content. We think operating leverage opportunities demonstrate EBITDA growth outpacing revenue growth in both segments. FOXA repurchased $100M in shares in Q3 and maintains a strong balance sheet with $3.6B cash and $6.61B in total debt outstanding as of March 31, 2026.

$FOXA

Research52d ago

Enbridge Target Raised To C$73 From C$72, Keeps Sector Perform at National Bank On Q1 and As "Project Backlog Filling Up Nicely"

$ENB.TO

Showing 2961-2980 of 6464